仁度生物(688193) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥37,068,338.31, a decrease of 47.37% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥1,849,404.75, showing a slight increase of 0.89% year-on-year, while the year-to-date net profit was a loss of ¥8,343,228.52, down 135.12%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥130,708.86, a decrease of 102.80% year-on-year, with a year-to-date loss of ¥14,424,990.54, down 215.58%[5] - Net profit for the third quarter of 2023 was -8,343,228.52, compared to a net profit of 23,754,699.23 in the same quarter of 2022, indicating a significant decline[23] - Operating profit for the third quarter of 2023 was -11,284,199.67, compared to 30,640,379.75 in the same quarter of 2022[23] Cash Flow - The net cash flow from operating activities for Q3 2023 was ¥1,928,682.49, compared to a negative cash flow of ¥12,018,719.88 for the same period last year[6] - Net cash flow from operating activities for the first nine months of 2023 was -12,018,719.88 CNY, an improvement from -15,431,886.63 CNY in the previous year[24] - Cash inflow from investment activities totaled 589,138,811.22 CNY, down from 744,498,273.44 CNY in the same period last year[25] - Net cash flow from investment activities was 398,397,394.59 CNY, a significant recovery from -110,972,110.31 CNY in the previous year[25] - The company reported a decrease in cash received from sales of goods and services, totaling 155,386,544.15 CNY, compared to 197,763,268.28 CNY in the previous year[24] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥1,047,715,622.76, a decrease of 3.77% from the end of the previous year[6] - The company's total assets decreased to ¥1,047,715,622.76 from ¥1,088,721,710.38, reflecting a decline of about 3.8%[18] - Total liabilities as of the end of the third quarter of 2023 were 96,395,364.24, down from 127,337,004.79 at the end of the previous year[20] - Total equity attributable to shareholders was 951,320,258.52, a slight decrease from 961,384,705.59 in the previous year[20] Research and Development - Research and development expenses totaled ¥11,103,681.12 for Q3 2023, a decrease of 2.70% year-on-year, while the R&D expenses accounted for 29.95% of operating revenue, an increase of 13.75 percentage points[6] - Research and development expenses for the first three quarters of 2023 were 29,704,497.58, an increase from 26,085,664.60 in the same period of 2022, showing a growth of 10.0%[22] Market and Demand - The decline in revenue and net profit was attributed to a significant drop in demand for pandemic-related testing products compared to the previous year[10] - The company has not disclosed any new product developments or market expansion strategies in the current report[16] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported during this period[15] Earnings Per Share - The basic earnings per share for Q3 2023 was ¥0.04, a decrease of 50.00% year-on-year, while the diluted earnings per share was also ¥0.04, reflecting the same decline[6] - Basic earnings per share for Q3 2023 were -0.21 CNY, compared to 0.71 CNY in the same period last year[24] Other Financial Metrics - The company reported a total of ¥1,718,695.89 in non-recurring gains and losses for the year-to-date, down from ¥6,081,762.02 in the previous year[9] - Other income for the first three quarters of 2023 was 1,306,434.90, down from 6,988,182.69 in the same period of 2022, a decrease of 81.3%[22] - The company reported a decrease in sales expenses to 67,835,643.87 from 100,913,576.40 in the same period of 2022, a reduction of 32.7%[22] - The company's deferred income tax liabilities were 1,198,062.49, down from 1,719,057.45 in the previous year, indicating a decrease of 30.2%[20]